Research Report on China's Antithrombotic Drug Market, 2013-2017
Thrombosis refers to the formation of local blood clots. Among it, artery thrombosis can cause myocardial infarction, stroke, acute coronary syndrome, peripheral arterial diseases, etc.; venous thrombosis can cause pulmonary embolism. Arteriovenous thrombosis is the primary reason for incidence and death of cardiovascular diseases, which is also one of the important causes for death of cancer patients.
Nowadays, cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) are severely threatening the life and health of the elderly worldwide. Cardiac-cerebral thrombotic diseases are called as the No.1 killer of the life and health of human beings currently. Cardiac-cerebral thrombotic diseases are characterized by high incidence rate, mortality rate and disability rate as well as suddenness. Since the reform and opening up, because of the continuous improvement in people's living standards as well as the rise in aging trend, the incidence rate of cardiac-cerebral thrombotic diseases continuously rises in China. According to statistics, the proportion of people dying from cardiac-cerebral thrombotic diseases already exceeds 70% in the dead aged above 60 in China's large cities. At present, the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients tend to be increasingly young.
It is reported that at present, over 7 million patients suffer from acute cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) in China annually. Among them, nearly half of the patients die; in survival patients, nearly two-thirds of them are maimed or completely lose self-care ability of daily living. Cardiac-cerebral thrombotic diseases cause not only pain to patients but also huge economic burdens to their families.
Antithrombotic drugs are used for the prevention and treatment of thromboembolic diseases, with the emphasis on prevention. Clinically, they are mainly used for the treatment and prevention of acute myocardial infarction and stroke embolism, which can reduce rates of re-infarction and mortality; they can be used for the prevention of heart valve replacement surgery postoperative thrombosis and the treatment of occlusive peripheral vascular diseases, intermittent claudication, unstable angina pectoris, etc. At present, the fast-growing indication is the prevention of deep vein thrombosis after orthopedic surgeries (such as knee and hip replacement surgeries as well as abdominal surgery).
Antithrombotic drugs are divided into anticoagulants, anti-platelet aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The market growth rate was consecutively over 20% from 2006 to 2012. The market size of hospital-use antithrombotic drugs reaches CNY 9.92 billion in 2012, with an increase of 21.9% YOY.
As the population further aging in China, on one hand, the incidence rate of vascular embolic diseases rises year by year; on the other hand, surgeries such as the interventional treatment of cardiovascular and cerebrovascular rapidly develop. The synchronous follow-up of anti-freezing, anti-platelet and lowering the blood lipid treatment after the stent surgery, promotes the capacity expansion of China's antithrombotic drug market. The market size of China's hospital-use antithrombotic drugs is expected to be over CNY 20 billion in 2017.
More following information can be acquired through this report:
Nowadays, cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) are severely threatening the life and health of the elderly worldwide. Cardiac-cerebral thrombotic diseases are called as the No.1 killer of the life and health of human beings currently. Cardiac-cerebral thrombotic diseases are characterized by high incidence rate, mortality rate and disability rate as well as suddenness. Since the reform and opening up, because of the continuous improvement in people's living standards as well as the rise in aging trend, the incidence rate of cardiac-cerebral thrombotic diseases continuously rises in China. According to statistics, the proportion of people dying from cardiac-cerebral thrombotic diseases already exceeds 70% in the dead aged above 60 in China's large cities. At present, the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients tend to be increasingly young.
It is reported that at present, over 7 million patients suffer from acute cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) in China annually. Among them, nearly half of the patients die; in survival patients, nearly two-thirds of them are maimed or completely lose self-care ability of daily living. Cardiac-cerebral thrombotic diseases cause not only pain to patients but also huge economic burdens to their families.
Antithrombotic drugs are used for the prevention and treatment of thromboembolic diseases, with the emphasis on prevention. Clinically, they are mainly used for the treatment and prevention of acute myocardial infarction and stroke embolism, which can reduce rates of re-infarction and mortality; they can be used for the prevention of heart valve replacement surgery postoperative thrombosis and the treatment of occlusive peripheral vascular diseases, intermittent claudication, unstable angina pectoris, etc. At present, the fast-growing indication is the prevention of deep vein thrombosis after orthopedic surgeries (such as knee and hip replacement surgeries as well as abdominal surgery).
Antithrombotic drugs are divided into anticoagulants, anti-platelet aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The market growth rate was consecutively over 20% from 2006 to 2012. The market size of hospital-use antithrombotic drugs reaches CNY 9.92 billion in 2012, with an increase of 21.9% YOY.
As the population further aging in China, on one hand, the incidence rate of vascular embolic diseases rises year by year; on the other hand, surgeries such as the interventional treatment of cardiovascular and cerebrovascular rapidly develop. The synchronous follow-up of anti-freezing, anti-platelet and lowering the blood lipid treatment after the stent surgery, promotes the capacity expansion of China's antithrombotic drug market. The market size of China's hospital-use antithrombotic drugs is expected to be over CNY 20 billion in 2017.
More following information can be acquired through this report:
- Incidence of Thrombosis in China
- Market Situation of China's Antithrombotic Drugs in Hospitals
- China's Major Antithrombotic Drug Manufacturers and Competition
- Development Trend of Antithrombotic Drugs in China
- Antithrombotic Drug Manufacturers
- Pharmaceutical Trade Enterprises
- Hospitals
- Investors/Research Institutions Focusing on Pharmaceutical Industry
1 OVERVIEW ON ANTITHROMBOTIC DRUGS
1.1 Overview on Thrombosis
1.2 Overview on Global Antithrombotic Drugs
1.2.1 Classification of Antithrombotic Drugs
1.2.2 Anticoagulants
1.2.3 Anti-platelet Aggregation Drugs
1.2.4 Thrombolytic Drugs
1.2.5 Overview on Antithrombotic Drug Market
2 ANALYSIS ON CHINA'S ANTITHROMBOTIC DRUG MARKET, 2007-2012
2.1 Market Size of Hospital-use Antithrombotic Drugs
2.2 Market Share of Hospital-use Various Antithrombotic Drugs
2.3 Market Share of Hospital-use Antithrombotic Drugs
2.4 Market Growth Rates of Various Hospital-use Antithrombotic Drugs
3 ANALYSIS ON MAJOR VARIETIES OF ANTITHROMBOTIC DRUGS IN CHINA'S MARKET
3.1 Heparin Drugs
3.2 Lumbrokinase
3.3 Urokinase
3.4 Sodium Ozagrel and Clopidogrel
3.4.1 Sodium Ozagrel
3.4.2 Clopidogrel
3.5 Rivaroxaban
3.6 Cilostazol
3.7 Alteplase
3.8 Propyl Gallate
4 PRICES OF CHINA'S MAJOR ANTITHROMBOTIC DRUGS FOR REFERENCE, 2012
5 PREDICTION ON DEVELOPMENT OF ANTITHROMBOTIC DRUGS
5.1 Prediction on Market Size
5.2 Technology Trend
1.1 Overview on Thrombosis
1.2 Overview on Global Antithrombotic Drugs
1.2.1 Classification of Antithrombotic Drugs
1.2.2 Anticoagulants
1.2.3 Anti-platelet Aggregation Drugs
1.2.4 Thrombolytic Drugs
1.2.5 Overview on Antithrombotic Drug Market
2 ANALYSIS ON CHINA'S ANTITHROMBOTIC DRUG MARKET, 2007-2012
2.1 Market Size of Hospital-use Antithrombotic Drugs
2.2 Market Share of Hospital-use Various Antithrombotic Drugs
2.3 Market Share of Hospital-use Antithrombotic Drugs
2.4 Market Growth Rates of Various Hospital-use Antithrombotic Drugs
3 ANALYSIS ON MAJOR VARIETIES OF ANTITHROMBOTIC DRUGS IN CHINA'S MARKET
3.1 Heparin Drugs
3.2 Lumbrokinase
3.3 Urokinase
3.4 Sodium Ozagrel and Clopidogrel
3.4.1 Sodium Ozagrel
3.4.2 Clopidogrel
3.5 Rivaroxaban
3.6 Cilostazol
3.7 Alteplase
3.8 Propyl Gallate
4 PRICES OF CHINA'S MAJOR ANTITHROMBOTIC DRUGS FOR REFERENCE, 2012
5 PREDICTION ON DEVELOPMENT OF ANTITHROMBOTIC DRUGS
5.1 Prediction on Market Size
5.2 Technology Trend
SELECTED CHARTS
Chart Market Size of Global Platelet Aggregation Inhibitors, 2007-2011
Chart Antithrombotic Drugs in the Top 50 Bestselling Drugs Globally, 2011
Chart Market Size of China's Antithrombotic Drugs in Hospitals, 2007-2012
Chart Market Shares of Major Varieties of China's Antithrombotic Drugs in Hospitals, 2007-2011
Chart Top 20 Antithrombotic Drug Manufacturers in China's Hospital Market, 2007-2011
Chart Market Share of China's Low Molecular Weight Heparin Sodium Enterprises in Hospital Drugs, 2010-2011
Chart Specifications and Reference Prices of Major Antithrombotic Drugs in China's Market, 2012
Chart Market Share of China's Alteplase Enterprises in Hospital Drugs, 2010-2011
Chart Prediction on Market Size of China's Antithrombotic Drugs in Hospitals, 2013-2017
Chart Market Size of Global Platelet Aggregation Inhibitors, 2007-2011
Chart Antithrombotic Drugs in the Top 50 Bestselling Drugs Globally, 2011
Chart Market Size of China's Antithrombotic Drugs in Hospitals, 2007-2012
Chart Market Shares of Major Varieties of China's Antithrombotic Drugs in Hospitals, 2007-2011
Chart Top 20 Antithrombotic Drug Manufacturers in China's Hospital Market, 2007-2011
Chart Market Share of China's Low Molecular Weight Heparin Sodium Enterprises in Hospital Drugs, 2010-2011
Chart Specifications and Reference Prices of Major Antithrombotic Drugs in China's Market, 2012
Chart Market Share of China's Alteplase Enterprises in Hospital Drugs, 2010-2011
Chart Prediction on Market Size of China's Antithrombotic Drugs in Hospitals, 2013-2017
